Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine.

Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J

Viana R;Moyo S;Amoako DG;Tegally H;Scheepers C;Althaus CL;Anyaneji UJ;Bester PA;Boni MF;Chand M;Choga WT;Colquhoun R;Davids M;Deforche K;Doolabh D;du Plessis L;Engelbrecht S;Everatt J;Giandhari J;Giovanetti M;Hardie D;Hill V;Hsiao NY;Iranzadeh A;Ismail A;Joseph C;Joseph R;Koopile L;Kosakovsky Pond SL;Kraemer MUG;Kuate-Lere L;Laguda-Akingba O;Lesetedi-Mafoko O;Lessells RJ;Lockman S;Lucaci AG;Maharaj A;Mahlangu B;Maponga T;Mahlakwane K;Makatini Z;Marais G;Maruapula D;Masupu K;Matshaba M;Mayaphi S;Mbhele N;Mbulawa MB;Mendes A;Mlisana K;Mnguni A;Mohale T;Moir M;Moruisi K;Mosepele M;Motsatsi G;Motswaledi MS;Mphoyakgosi T;Msomi N;Mwangi PN;Naidoo Y;Ntuli N;Nyaga M;Olubayo L;Pillay S;Radibe B;Ramphal Y;Ramphal U;San JE;Scott L;Shapiro R;Singh L;Smith-Lawrence P;Stevens W;Strydom A;Subramoney K;Tebeila N;Tshiabuila D;Tsui J;van Wyk S;Weaver S;Wibmer CK;Wilkinson E;Wolter N;Zarebski AE;Zuze B;Goedhals D;Preiser W;Treurnicht F;Venter M;Williamson C;Pybus OG;Bhiman J;Glass A;Martin DP;Rambaut A;Gaseitsiwe S;von Gottberg A;de Oliveira T